Will Star Health, HDFC ERGO, ICICI Lombard, and Niva Bupa cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Jakafi is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by CDSCO?

The CDSCO named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; CDSCO review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Indian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The State Medical Council and the CDSCO Zonal Office verifies the active license; the CDSCO application records both the prescribing physician and the dispensing facility.

Can I receive Jakafi at home?

The dispensing facility must be Indian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 14,500 to 17,000 per month. Delivered quote within 24h.Get my quote

Jakafi access in India: the CDSCO named-patient pathway

How patients in the Republic of India legally obtain Jakafi (ruxolitinib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in India access Jakafi (ruxolitinib) for intermediate or high-risk myelofibrosis, polycythaemia vera with inadequate response to or intolerance of hydroxyurea, and steroid-refractory acute or chronic graft-versus-host disease under the FDA label through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in INR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Jakafi reaches patients in India

Jakafi (ruxolitinib, oral JAK1 and JAK2 inhibitor, FDA-approved 2011 for intermediate or high-risk myelofibrosis, 2014 for polycythaemia vera with inadequate response to or intolerance of hydroxyurea, 2019 for steroid-refractory acute graft-versus-host disease, and 2021 for steroid-refractory chronic graft-versus-host disease in patients 12 years and older; marketed by Incyte) is registered in India through Novartis (the ex-US licensee for ruxolitinib) and appears on the CDSCO SUGAM database for selected presentations. Where the prescribed dose strength, indication, or paediatric cGVHD dosing is not locally stocked, Indian patients access Jakafi via Form 12-A personal-use import under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945; the Form 12-B permit issues within one to two working days per cdsco.gov.in/consumer/Drugs-for-Personal-Use. Hospital-led imports use CT Form-16 under the New Drugs and Clinical Trials Rules 2019, particularly for BMT-unit administration in steroid-refractory cGVHD. The Jakafi-specific clinical justification must document the indication and disease-specific criteria: for MF, DIPSS or DIPSS-plus risk score and platelet-based starting dose (5 mg, 10 mg, 15 mg, 20 mg BID); for PV, intolerance or inadequate response to hydroxyurea per the FDA label; for steroid-refractory aGVHD or cGVHD, the steroid-refractoriness definition and prior systemic therapy lines. CBC surveillance schedule per the FDA label is referenced in the supporting medical report.

Where Jakafi is dispensed in India

Jakafi is an oral chronic therapy administered in haematology and bone marrow transplant outpatient settings with serial CBC surveillance. Indian tertiary nodes for ruxolitinib include Tata Memorial Hospital Adult Haematolymphoid DMG in Mumbai at tmc.gov.in; AIIMS New Delhi Department of Haematology and BMT Unit at aiims.edu; CMC Vellore Department of Clinical Haematology (a global reference centre for myeloproliferative neoplasms and post-BMT GVHD) at clin.cmcvellore.ac.in; PGIMER Chandigarh Department of Haematology; Tata Medical Center Kolkata Adult Haematology and BMT; Apollo Hospitals MPN clinics in Chennai, Delhi, and Hyderabad; Fortis Memorial Research Institute BMT in Gurugram; and Medanta The Medicity Department of Haematology and BMT. CMC Vellore, AIIMS, and TMC publish departmental leadership and run structured MPN and BMT clinics; they are the primary nodes for diagnostic confirmation by JAK2 V617F, CALR, or MPL mutation testing and DIPSS-plus risk stratification, and for steroid-refractory cGVHD post-allo-BMT.

What Jakafi costs in India

The US reference WAC for Jakafi is approximately USD 15,000 to USD 17,000 per 30-day supply at the 20 mg twice-daily standard MF dose; PV and lower-platelet starting doses run lower. Annual WAC at maintenance dose ranges USD 180,000 to USD 200,000. Source: Drugs@FDA at accessdata.fda.gov/scripts/cder/daf and Incyte published pricing. Novartis India distributes ruxolitinib (brand: Jakavi) for the registered indications; reporting from Indian patient organisations and pharmacy-distributor channels places the locally-procured INR price for Jakavi 20 mg in the range of INR 32,000 to INR 45,000 per 14-tablet pack depending on stock window. NPPA at nppaindia.nic.in has not published a DPCO ceiling for ruxolitinib as of 2026-05-31. Price snapshot: 2026-05-31. Cost layers: ambient-temperature logistics into India (low four-figure USD; oral tablet), CDSCO Form 12-B permit (nominal), haematology consultation and serial-CBC surveillance fees, and Reserve Meds concierge fee itemised separately.

Funding and access barriers for Jakafi in India

MF and PV affect predominantly older adults with annual incidence approximately 1 per 100,000 each; the Indian MPN registry maintained at CMC Vellore documents the patient population. Public-sector funding: RAN at mohfw.gov.in provides BPL assistance at designated super-specialty hospitals up to a defined ceiling; HMCPF earmarks for cancer treatment at designated RCCs. Ayushman Bharat PM-JAY does not consistently list ruxolitinib by name. State schemes (Tamil Nadu CMCHIS, Kerala KASP, Karnataka, Andhra Aarogyasri) include selected myeloproliferative-neoplasm packages with state-specific drug lists. Private insurance: standalone health insurers and general insurers' health portfolios increasingly cover ruxolitinib on higher-tier individual and corporate group policies with prior authorisation and step-therapy documentation (hydroxyurea failure or intolerance for PV; risk-stratification documentation for MF; corticosteroid-refractory documentation for GVHD). Novartis India operates the Jakavi Patient Support Programme through registered haematology centres; eligibility is means-tested and includes co-pay assistance. For steroid-refractory cGVHD, the FDA label dose (10 mg BID) often runs concurrent with BMT-unit transplantation costs, which Ayushman Bharat and state schemes partially cover. Crowdfunding (Ketto, Milaap, ImpactGuru) is a documented complementary route for sustained ruxolitinib funding.

Recent regulatory and access news for Jakafi

FDA-approved (June 2023) ruxolitinib cream for vitiligo in patients 12 years and older (Opzelura) is a separate product from oral Jakafi but shares the active. FDA continues post-marketing surveillance on long-term safety, particularly serious infections and second primary malignancies, with periodic labelling updates published at accessdata.fda.gov/scripts/cder/daf. EMA has retained the Jakavi label across MF, PV, GVHD, and chronic GVHD; the European public assessment reports are at ema.europa.eu/medicines. CDSCO Notifications at cdsco.gov.in/Notifications have not issued a ruxolitinib-specific bulletin over the last 12 months as of 2026-05-31. NPPA has not added ruxolitinib to a DPCO ceiling list.

Where Reserve Meds fits in Jakafi cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Jakafi specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Jakafi case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Indian haematology at Tata Memorial and CMC Vellore co-ordinates JAK inhibitor supply for MPN with FDA-labelled CBC and lipid monitoring; Rule 36 personal import applies.

Next step

If your Indian physician has prescribed Jakafi and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Jakafi case Or message us on WhatsApp